$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西林联合来曲唑可延长乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑可明显延长乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA1/2突变的晚期乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼在局部晚期,非炎性乳腺癌的治疗
2025-10-19 11:44:20
Check Details
帕博西尼在ER 阳性和(或)HER-2 阴性晚期乳腺癌的治疗
2025-10-19 11:44:20
Check Details
帕博西尼的临床应用综述
2025-10-19 11:44:20
Check Details
帕博西林与来曲唑联合治疗乳腺癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
PARP抑制剂尼拉帕尼治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼不单可以治疗乳腺癌,也可用于其他癌症用药
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑治疗乳腺癌有显著疗效
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗转移性乳腺癌的实验数据
2025-10-19 11:44:20
Check Details
1
2
...
1653
1654
1655
1656
1657
1658
1659
...
4158
4159
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
2
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
3
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
4
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
5
Lapatinib: Proper Administration Guide and Key Precautions
6
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
7
Cemiplimab Storage and Handling Guide
8
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
9
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
10
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
11
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
12
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1